Podcasts about Memorial Sloan Kettering Cancer Center

Parkinson's is a disease that afflicts an estimated 90,000 Americans every year. Current treatment focuses on managing its many symptoms as there is no cure. But a new stem cell-based therapy that creates nerve cells is showing early promise. What's behind this incredible discovery and just how hopeful should patients be? Two of the doctors leading this development, Dr. Lorenz Studer and Dr. Viviane Tabar of Memorial Sloan Kettering Cancer Center, join The Excerpt to share the journey behind this exciting new development.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue: “Computer-Aided Design and Manufacturing in Free Fibula Reconstruction of the Mandible: Comparison of Long-Term Outcomes with the Conventional Technique” by Bengur, Humar, Saadoun, et al.  Read the article for FREE: https://bit.ly/CADCAMRecon Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS

In today's episode, supported by Azurity Pharmaceuticals, we spoke with Michael J. Mauro, MD, about treatment adherence with nilotinib (Tasigna/Danziten) in patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML). Dr Mauro is an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Mauro discussed barriers to nilotinib treatment adherence in patients with Ph-positive CML, ways that nonadherence can diminish quality of life and clinical response to treatment, ways that the new formulation of nilotinib addresses adherence issues by reducing the need for fasting, and ongoing research into alternative formulations of other agents that may further improve CML treatment efficacy and tolerability.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue: “Legislative Impact and Persistent Disparities: Postmastectomy Breast Reconstruction Rates in the United States among 224,506 Patients” by Schafer, Ho, Potoczak, et al. Read the article for FREE: https://bit.ly/LegislativeReconRate Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS

Cancer is among the most common and feared diseases in the modern world. Dr. Selwyn Vickers—president and CEO of Memorial Sloan Kettering Cancer Center—joins host Mark Labberton to discuss how precision oncology, data, and faith are transforming cancer treatment. A distinguished cancer surgeon and pancreatic cancer researcher, Vickers explains how groundbreaking advances in genomics, immunotherapy, and AI are transforming once-lethal diagnoses into survivable and even chronic conditions. Together, they explore not only the cutting-edge science of cancer care but also the spiritual, emotional, and social dimensions that affect every patient and caregiver. Resonating with themes of suffering, hope, and resurrection, this conversation offers clarity, compassion, and courage for all who are affected by cancer—from those newly diagnosed, to medical professionals, to grieving families and curious listeners. Episode Highlights “We're getting to a point where we will, in the next five to seven years, have a much better chance to cure people—and to make pancreatic cancer a chronic illness.” “We are in what's somewhat coined the golden age of cancer research.” “Cancer is a disease that creates an existential threat in ways no other illness does.” “If a tumour forms, it means your body's immune system has made a social contract with the cancer.” “We changed the diagnosis in 10–12 percent of the patients who come to us—sometimes from cancer to no cancer.” “Cancer care is a team sport. And our patients often inspire us more than we help them.” Helpful Links & Resources Memorial Sloan Kettering Cancer Center BioNTech – creators of mRNA vaccines for COVID and cancer CAR T-Cell Therapy Overview (Cancer.gov) Tim Keller on cancer and hope Emma Thompson's Wit (HBO) BRCA1 and BRCA2 Genes and Cancer Risk MSK-IMPACT: Next-Gen Tumor Profiling About Selwyn Vickers Selwyn M. Vickers, MD, FACS, is the president and CEO of Memorial Sloan Kettering Cancer Center (MSK) and the incumbent of the Douglas A. Warner III Chair. He assumed the role on September 19, 2022. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. He is a member of the National Academy of Medicine and the Johns Hopkins Society of Scholars. He has served on the Johns Hopkins School of Medicine Board of Trustees and the Johns Hopkins University Board of Trustees. Additionally, he has served as president of the Society for Surgery of the Alimentary Tract and the Southern Surgical Association. Vickers is the immediate past president of the American Surgical Association. He also continues to see patients. In 1994, he joined the faculty of the University of Alabama at Birmingham (UAB) as an assistant professor in the Department of Surgery, where he was later appointed to professor and the John H. Blue Chair of General Surgery. In 2006, Vickers left UAB to become the Jay Phillips Professor and Chair of the Department of Surgery at the University of Minnesota Medical School. Born in Demopolis, Alabama, Vickers grew up in Tuscaloosa and Huntsville. He earned baccalaureate and medical degrees and completed his surgical training (including a chief residency and surgical oncology fellowship) at the Johns Hopkins University. Vickers completed two postgraduate research fellowships with the National Institutes of Health and international surgical training at John Radcliffe Hospital of Oxford University, England. Vickers and his wife, Janice, who is also from Alabama, have been married since 1988. They have four children. Show Notes The ongoing threat and fear of cancer How Selwyn Vickers got into medicine Pancreatic cancer: Vickers's expertise “We are in what's somewhat coined the golden age of cancer research.” Sequencing the human genome “Is there a drug that might target the mutation that ended up creating your cancer?” Cancer as both a medical and existential diagnosis The revolution of precision oncology through human genome sequencing ”It takes a billion cells to have a one centimetre tumor.” Immunotherapy: checkpoint inhibition, CAR T-cell therapy, and vaccines Cellular therapy:   ”Taking a set of their normal cells and re-engineering them to actually go back and target and attack their tumors. … We've seen patients who had initially a 30 percent chance of survival converted to an 80 percent chance of survival.” “We know in many tumours there's something called minimal residual disease.” “Immunizing yourself against cancer is a significant future opportunity.” Managing the power of data with AI and computational oncology Cancer-care data explosion: the role of computational oncologists Cancer vaccines: breakthrough mRNA treatment for pancreatic cancer ”Didn't ultimately win. We had to suffer through her losing her life, but was so appreciative that she got much more than the six months she was promised.” Tumour misdiagnoses and the importance of specialized expertise Pancreatic cancer challenges: immune cloaking and late-stage detection In the past, one in four would die from the operation for removing pancreatic cancer Long-term survival Future of cancer detection: AI-based medical record analysis and blood biopsies More accurate blood tests to confirm conditions Using AI to select those who are high-risk for cancer Pastor Tim Keller died of pancreatic cancer. In the past, “your doctor … helped you learn how to die.” ”[God's] given man the privilege to discover those things that have been hidden. And over time we've gradually uncovered huge opportunities to impact people's lives.” The state of breast cancer research and treatment “If you get the diagnosis of breast cancer, you have a 90 percent chance to survive and beat it over a five-year period of time.” ”In general, we're in a great state of understanding how to treat breast cancer, how to detect it early, and then have selective and targeted mechanisms to prevent it from coming back.” Prostate cancer research and treatment Theranostics: using a specific antibody to target cancer cells specifically Pediatric cancer:  ”We actually treat more children for cancer than any hospital in America now, but in general, the survival for pediatric cancers is greater than 80 percent.” Emotional, psychological, and spiritual toll of cancer: importance of psycho-oncology How Sloan Kettering developed psycho-oncology to help cancer patients with mental and spiritual health Personal story: how a cafeteria worker empowers patients through food choices “We give back to them the right to choose what they get to have on their tray.” Cancer treatment is a team sport. Wit (film, Broadway play)—actress Emma Thompson plays a cancer patient studying the work of John Donne on death Socioeconomic and racial disparities in cancer care outcomes The healing role of community, support teams, and compassionate listening The importance of listening to cancer patients who are preparing to die The spiritual courage of patients and the transformative power of faith “Our patients often help us. We see the grace with which they often handle that journey.” The inspiration behind becoming a doctor: family legacy and human impact Terminal care: the sacred responsibility of walking with patients to the end Cancer research and treatment as a Christian vocation and expression of humanity Production Credits

In today's episode, supported by Revolution Medicines, we spoke with Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, about 2 important abstracts presented at the 2024 AACR Annual Meeting that explore novel RAS-targeted approaches in non–small cell lung cancer (NSCLC). Our discussion focused on early clinical findings with zoldonrasib (RMC-9805) and daraxonrasib (RMC-6236), both of which are RAS(ON) inhibitors under investigation for the treatment of patients with RAS-mutant NSCLC. Zoldonrasib, a KRAS G12D-selective tri-complex inhibitor, was evaluated in a phase 1 trial (NCT06040541) in patients with previously treated, advanced KRAS G12D–mutated solid tumors, including NSCLC. Daraxonrasib, a multi-selective RAS(ON) inhibitor, was highlighted in another phase 1 trial (NCT05379985) in patients with advanced RAS-mutant tumors, including previously treated NSCLC; notably, this AACR presentation focused on the association between early on-treatment circulating tumor DNA level reduction and clinical response with the agent. In this episode, Dr Arbour shared insights into the mechanisms of action behind these therapies, their respective clinical trial designs, and the potential implications that early data with the agents may have for the evolving RAS-mutant NSCLC treatment paradigm.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue: “The Financial Impact of a Cosurgeon in Breast Microsurgery” by DeVito, Ke, Park, et al. Read the article for FREE: https://bit.ly/CosurgeonFinance Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS

Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/How would your life transform during a 30-day water fast?Dr. Katie Deming is joined by her client Donna DiPane and medical oncologist Dr. Jason Konner from Memorial Sloan Kettering Cancer Center to share an extraordinary healing journey. Donna recently completed a 30-day supervised water-only fast as part of her holistic approach to healing from ovarian cancer. What makes this story especially powerful is the collaborative relationship between conventional and holistic medicine.Chapters:00:17:00 – The fear wasn't just about cancer00:22:00 – I unzipped from my body00:31:00 – A message from God at 3 am00:38:00 – When the shell started to crack00:52:00 – Strip it all down to healThey explore how fasting goes far beyond physical detoxification. Donna shares the profound spiritual awakening she experienced, including receiving powerful messages during the night, connecting with her "light body," and finding a deep release from the fear that had dominated much of her life. Dr. Konner offers his perspective as a conventional oncologist, describing his initial concerns about safety and his surprise at witnessing Donna's transformation throughout the process - not just physically, but emotionally and spiritually.Listen and learn about what happens during a fast, from the physical challenges of the first week to the emotional and spiritual openings that can occur as the body and mind clear.Disclaimer: Never attempt prolonged fasting without proper medical oversight as it can be dangerous. Send us a text with your question (include your phone number)Join Dr. Katie at CANCER: FROM FEAR TO HOPE on May 8, 2025https://heal.regfox.com/heal-from-fear-to-hopeCode: KATIERESILIENCE10 Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatie MORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/6 Pillars of Healing Cancer Workshop Series - Click Here to EnrollWork with Dr. Katie: www.katiedeming.comFollow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Take a Deeper Dive into Your Healing Journey: Dr. Katie Deming's Linkedin Here Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER:The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose...

Dr. Fiona Lovely is a longevity, health and wellness expert with specialties in menopause medicine, functional neurology and functional medicine.  She is speaking to the topics of women's health around perimenopause and menopause. In this week's episode, Dr. Lovely sits down with Dr. Shelly Latte-Naor — board-certified internist, integrative medicine physician, and menopause care specialist — for a deeply insightful conversation on supporting menopause for all women and in particular,  in cancer survivors. With a background in mind-body medicine and a former leadership role at Memorial Sloan Kettering Cancer Center, Dr. Latte-Naor brings a wealth of expertise in treating treatment-induced menopause and its often-overlooked effects on women's health post-cancer. Together, they explore how cancer treatments like chemotherapy and hormone blockers can trigger sudden and severe menopausal symptoms, often overlooked in survivorship care. Dr. Latte-Naor breaks down the complexities of hormone therapy in breast cancer patients, including safe uses of local estrogen and emerging research on systemic HRT. The Nitty-Gritty: The hidden toll of cancer treatments: How chemotherapy and hormone blockers can fast-track intense menopause—and why the symptoms are so often dismissed. The truth about hormone therapy in breast cancer survivors: what's safe, what's not, and why the conversation is evolving Non-hormonal solutions for hot flashes, night sweats, and sleep issues—including breakthrough medications and integrative approaches Why sleep disruptions are so common after cancer—and how improving sleep can transform recovery, cognition, and mood The emotional toll of “survivorship shock” and how to rebuild trust in your body after treatment Why self-advocacy is critical—and how to ask for the care you deserve You'll hear about non-hormonal treatment options for:  hot flashes, night sweats, and sleep issues, and how foundational good sleep is to healing and recovery. She also shares powerful insights into the emotional experience of “survivorship shock” and why trauma-informed therapy and self-advocacy are key. If you or someone you know is navigating menopause after cancer (or you're just looking for more ways to support a loved one), this episode is a must-listen. It's a rallying cry for women to demand better care, advocate for themselves, and reframe survivorship as an ongoing journey—one that includes emotional healing, educated choices, and open, honest conversations. You can find more about Dr. Shelly Latte-Naor at shellylattenaormd.com and follow her on Instagram or TikTok. Thank you to our sponsors for this episode:

In this episode of It Takes Balls, Bob Jordan, a Brooklyn-based designer and snowboarder, shares the raw, emotional, and at times unbelievable journey of his testicular cancer diagnosis, treatment, and recovery.What began as a routine backcountry snowboarding trip ended with a bump, a tick bite, and a series of misdiagnoses that nearly cost Bob his life. From fighting for answers to confronting a flawed healthcare system, Bob shares how intuition, persistence, and community helped him survive one of the most challenging periods of his life.He opens up about the trauma of receiving a cancer diagnosis via his patient portal, poor bedside manners, and the gut-wrenching realization that his initial care team missed a critical tumor. After switching to Memorial Sloan Kettering Cancer Center, Bob finally received the expert attention he needed. He also shares what it was like to go through four grueling months of chemotherapy, why he trained his body for treatment, and how a bubble-wrapped snowboard session became a symbol of defiance and hope.But Bob's story doesn't end at remission. He dives into the mental health aftermath, financial strain, and the emotional weight of survivorship, offering an honest look at what it really means to heal. Through creativity, advocacy, and connection, including forming community through Reddit, Bob has turned his experience into a platform for others.Want to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Connect with Bob:https://www.instagram.com/factory808/https://www.808designs.comTheme song: No Time Like Now - Tom Willner www.tomwillner.com

In AARC's latest AARC Perspectives Podcast - Behind the Breath: A Day in the Life of a Cancer Care RT, we are joined by Michelle Rausen, MS, RRT, RRT-NPS, RRT-ACCS of Memorial Sloan Kettering Cancer Center and AARC VP of Membership and Customer Care, Monique Kimmel. Michelle discusses her insights, the emotional and psychological aspects of her work, why RTs in cancer-specific care are so critical, and how AARC is helping to bring the cancer care community together. Additional Resources:AARC Connect Cancer Care CommunityYouTube Live RecordingAbout our guest - Michelle Raussen, MS, RRT, RRT-NPS, RRT-ACCSSend us a textSupport the show

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Evan Matros, MD, discuss the following articles from the May 2025 issue:   “The Financial Impact of a Cosurgeon in Breast Microsurgery” by DeVito, Ke, Park, et al.   “Legislative Impact and Persistent Disparities: Postmastectomy Breast Reconstruction Rates in the United States among 224,506 Patients” by Schafer, Ho, Potoczak, et al.   “Computer-Aided Design and Manufacturing in Free Fibula Reconstruction of the Mandible: Comparison of Long-Term Outcomes with the Conventional Technique” by Bengur, Humar, Saadoun, et al.   Special guest, Evan Matros, MD is an attending surgeon, Vice Chair of Health Information Technology in the Department of Surgery, and the program director of the microsurgery fellowship at the Memorial Sloan Kettering Cancer Center in New York City. He completed his General Surgery and Plastic Surgery Residencies at Harvard Medical School followed by a microsurgery fellowship at Memorial Sloan Kettering Cancer Center. He also has received his MPH at Columbia University and Master of Medical Science degree from Harvard Medical School. Among his many accomplishments, Dr. Matros is the current vice president of the American Society for Reconstructive Microsurgery Council, he currently serves on the editorial board of the PRS Journal, and he is widely published in reconstructive microsurgery.   READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCMay25Collection   The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Cohort study evaluated the use of ablative radiation therapy (A-RT) as a noninvasive alternative to surgery in 25 patients with technically resectable pancreatic ductal adenocarcinoma (PDAC) who were ineligible for surgery due to comorbidities. Conducted at Memorial Sloan Kettering Cancer Center between 2016 and 2022, the study found that A-RT, delivered with high precision and dose intensity, provided promising local control and overall survival, with a 2-year OS rate of 43.7% and manageable toxicity. Despite advanced age, poor performance status, and limited chemotherapy use in the cohort, outcomes suggest A-RT may be a viable local therapy for select patients with resectable PDAC, warranting further prospective investigation.Link to Arcticlehttps://jamanetwork.com/journals/jamaoncology/article-abstract/2832566

Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here.

The International Psycho-Oncology Society (IPOS) deemed April 9th, 2025, the first-ever World Psycho-Oncology Day (WPOD). This day was meant to spread awareness of the importance of prioritizing psychosocial care for patients with all types of cancer as well as to honor Jimmie C. Holland, MD. Prior to WPOD, CancerNetwork® spoke with Cristiane Decat Bergerot, PhD, BS, MS, a psychologist and the head of supportive care at Grupo Oncoclinicas in Brazil, and a member of IPOS, about the importance of psychosocial care and the impact it has on patients with cancer. As stated by Bergerot and listed on the official IPOS website, the primary goals of WPOD are as follows: raise awareness, honor Jimmie Holland, engage stakeholders, promote action, and support fundraising efforts.1 These goals are geared towards paying homage to the history of psycho-oncology and pushing for a more advanced future. “We aim to empower patients, caregivers, and healthcare professionals, fostering a future where psychosocial support is an integral part of oncology worldwide,” Bergerot said.  Psycho-oncology has become more prevalent as a cancer care field since Jimmie C. Holland, MD, worked to help found it in the 1970s. Holland, a “pioneer” of psycho-oncology, was the first ever Chief of Psychiatry Services—a department that was the first of its kind anywhere in the world—at Memorial Sloan Kettering Cancer Center, and a founding member of IPOS.  Bergerot stated that, in her work, she sees that patients who receive psychological support exhibit improved pain management and quality of life. Trials now focus more on end points such as quality of life and patient-reported outcomes, and guidelines have emerged to create standards of care. The National Comprehensive Cancer Network and the American Society of Clinical Oncology each offer guidelines that detail how to manage patient distress as they progress through cancer therapy.2,3 Distress screenings and earlier recommendations for palliative care have also become more standard in treatment.  As for the future, Bergerot highlighted that psychosocial care needs to be more integrated into care as a necessary, rather than optional, component. New developments around the world, however, have created a landscape where telehealth and new research demonstrate the potential to help psycho-oncology grow rapidly.  References 1.        World Psycho-Oncology Day (WPOD). IPOS. Accessed April 2, 2025. https://tinyurl.com/43c9rr2c 2.        Distress during cancer care. NCCN. 2024. Accessed April 2, 2025. https://tinyurl.com/ycxxvnmt 3.        Andersen BL, Lacchetti C, Ashing K, et al. Management of anxiety and depression in adult survivors of cancer: ASCO guideline update. J Clin Oncol. 2023;41(18):3426-3453. doi:10.1200/JCO.23.00293

Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

In today's episode, we invited experts from across oncology specialties to discuss the long-term effects of the COVID-19 pandemic—the onset of which occurred 5 years ago. Our guests shared how the pandemic's lingering effects continue to shape patient care. We heard from:  Ramez N. Eskander, MD, a gynecologic oncologist and assistant professor of obstetrics, gynecology, and reproductive sciences at the University of California San Diego Health Rachel N. Grisham, MD, an associate attending physician at Memorial Sloan Kettering Cancer Center in New York, New York Benjamin Herzberg, MD, an assistant professor of medicine at Columbia University Medical Center and an oncologist at Herbert Irving Comprehensive Cancer Center in New York, New York  Kelly McCann, MD, PhD, an assistant professor and breast medical oncologist at UCLA Health's David Geffen School of Medicine in Los Angeles, California Gregory Roloff, MD, a hematologist/oncologist at the University of Chicago Medicine in Illinois

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

So You've Been Diagnosed With Cancer: Now What? That “now what” is the big question everyone faces when they hear those dreaded worlds: You have cancer. Tune into this episode to hear some helpful advice from Heather's “chief of staff” (aka one of the best friends) Amy Dieterich, and Dr. Starr Mautner, a Board-certified surgeon with clinical expertise in breast surgical oncology of the Breast Center at Miami Cancer Institute, a part of Baptist Health South Florida. Bio: Starr Mautner, M.D., F.A.C.S. Dr. Mautner is a board-certified breast surgical oncologist at the Miami Cancer Institute (MCI) in Miami, Florida. She specializes in performing breast surgical procedures for women with breast cancer, high risk lesions, or women with a genetic predisposition to breast cancer. She grew up in South Florida and earned her undergraduate and medical school degrees as part of the University of Miami's 7-year Medical Scholars Program. She then completed her general surgery residency at Weill Cornell's New York Presbyterian Hospital and clinical fellowship in breast surgical oncology at Memorial Sloan Kettering Cancer Center before moving back to Miami to join the Miami Cancer Institute in 2015. She is the co-chair of the Memorial Sloan Kettering Alliance Education Committee and is very involved in community engagement and educational programs in South Florida. She is also the lead physician for breast surgical oncology clinical trials at MCI and a member of the Breast Cancer Alliance Medical Advisory Board. In her free time, she enjoys spending time with her husband and children exploring Miami or traveling on adventures around the world together. Bio: A dedicated philanthropist with a deep passion for supporting families and children, Amy Dieterich is committed to making a meaningful impact in healthcare and advocacy. As a member of the Chairman's Circle at NYU Hospital and the Children's Advisory Council of New York-Presbyterian Komansky Center for Children's Health, she plays a vital role in shaping initiatives that enhance pediatric care. Her leadership extends to Breakthrough T1D, where she has spearheaded giving campaigns and initiatives to advance research and support for those affected by Type 1 Diabetes. Beyond her philanthropic efforts, she is a strong advocate for women, fostering connections and uplifting women in business. A devoted mom of four boys, she embraces adventure and cherishes traveling with her family, always seeking new experiences and meaningful ways to give back. Find Yonni & Heather here https://www.herhealthcompass.com/

Dr. Sue Yom, Editor in Chief, co-hosts with Dr. Lachlan McDowell, Consultant Radiation Oncologist at the Princess Alexandra Hospital in Queensland, Australia and our journal's Head and Neck Cancer Section Editor. Guests are Dr. Sean McBride, Radiation Oncologist at Memorial Sloan Kettering Cancer Center and Chief of External Beam Radiotherapy at the Manhattan site, who authored an editorial, Oligometastatic HNSCC: Is SABR the Solution?, and Dr. Juliette Thariat, Professor in Radiation Oncology at Cancer Center Baclesse in Normandy, France, Secrétaire Nationale at the GORTEC, and first author of our featured article, Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.

Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes. CME information and select publications here.

March marks Multiple Myeloma Awareness Month, a crucial time to highlight advances in the treatment of this complex blood cancer. Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center, is currently serving as chair of i3 Health CME/NCPD activity, Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma. In this interview, Dr. Hashmi shares additional insights into the evolving role of transplantation in this disease and the importance of education and advocacy during Multiple Myeloma Awareness Month. Click the link for the full activity! https://bit.ly/4hyVwLn

Dermatologic toxicities associated with oncology treatment can significantly impact quality of life and treatment adherence for patients with breast cancer. The Association of Cancer Care Centers (ACCC) is committed to providing up-to-date guidance on managing these dermatologic side effects to enhance clinical outcomes. In this episode of CANCER BUZZ, Allison Gordon, MD, a supportive oncodermatologist at Memorial Sloan Kettering Cancer Center, discusses the dermatologic toxicities associated with breast cancer treatment. Dr Gordon explores preventive measures that oncologists can implement early in the treatment course and offers alternative resources for oncology clinicians when an oncodermatologist referral is not feasible. Additionally, she highlights capivasertib, a recently approved antineoplastic drug, and reviews its associated cutaneous adverse events, along with supportive care and management strategies. Thank you to AstraZeneca for their support of this program.   Allison Gordon, MD Dermatologist Memorial Sloan Kettering Cancer Center New York, NY   “Because many of these medications can cause dry skin, which can be debilitating for patients... [we recommend] using a thick ointment or cream moisturizer on their damp skin after they shower... it doesn't have to be anything expensive... I always recommend that to all patients regardless of what treatment they're on.”– Allison Gordon, MD    Additional Reading/Sources  ACCC Supportive Care Strategies for Dermatologic Toxicities Related to Cancer Therapies education program (https://www.accc-cancer.org/home/learn/comprehensive-cancer-care-services/dermatologic-toxicities?)   Targeted Therapy Side Effects – American Cancer Society  (https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy/side-effects.html)   Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569770/)   Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy (https://ascopubs.org/doi/10.1200/EDBK_289911)   Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatolgy Study Group (https://mascc.org/resources/mascc-guidelines/)   Guidelines for the Prevention and Treatment of Radiation-Induced Skin Reactions (https://mascc.org/resources/mascc-guidelines/)   Guidelines for Prevention and Management of Dermatological Toxicities Related to Anticancer Agents (https://pubmed.ncbi.nlm.nih.gov/33248228/)

Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes. CME information and select publications here.

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

This week, we'll delve into a cautionary tale: the "Radium Girls." These women were employed to paint glow in the dark numbers on watch faces and dials in the 1920s and 30s using radium paint. Assured that the paint was safe, the girls were instructed to shape their paintbrushes into sharp points with their own lips. But, turns out, ingesting radioactive radium paint isn't safe at all, and as the women became sick and sicker and died, the companies they worked for chose to gaslight them, refusing to take responsibility all while lining their pockets with profits. But these women fought back, standing up while laying down and their fight set an important precedent we can't afford to forget. Let's fix that. Support the show! Join the Patreon (patreon.com/historyfixpodcast)Buy some merchBuy Me a CoffeeVenmo @Shea-LaFountaineSources: International Atomic Energy Agency "What is Radiation"US Department of Energy "Nuclear Fuel Facts: Uranium"Library of Congress Blogs "Radium Girls: Living Dead Women"Wikipedia "Radium Girls"Memorial Sloan Kettering Cancer Center "Hot Times in 'Radium Hospital'"Mariecurie.org "Marie Curie the scientist"American Physical Society "Henri Becquerel Discovers Radioactivity"Northern Public Radio "Ottawa's 'Radium Girls' At Forefront of Worker Protections"Encyclopedia Britannica "Radium Girls: The Women Who Fought For Their Lives in a Killer Workplace"Shoot me a message!

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

This week, Jonathan is joined by Eytan Stein, Chief of the Leukaemia Service and an Attending Physician at Memorial Sloan Kettering Cancer Center, New York, USA.  Timestamps:      (00:00)-Introduction  (01:05)-The current landscape of treatments  (02:26)-The promise and peril of differentiation therapy  (05:55)-Highlighting the most impactful clinical trials  (08:38)-Epigenetics and the future of targeted therapies  (10:40)-The BEAT AML master clinical trial  (12:57)-The latest research into IDH inhibitors  (16:10)-Therapies for splicing factor mutations  (19:29)-Reducing patient fear with education   (22:46)-Stein's three wishes for healthcare   

Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.

Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.

As part of the US HUPO sponsored "Philly Express" series highlighting speakers at the upcoming 2025 US HUPO meeting in Philadelphia, Ben and Ben sit down to talk with Dr. Kojo Elenitoba-Johnson, Memorial Sloan Kettering Cancer Center.

In our February episode, we marked American Heart Month with Dr. Shivani Verma, an interventional cardiologist at Maimonides Medical Center. In this month's Key Note, Dr. Verma explains “broken heart syndrome,” a rare condition that can affect the heart muscle after an emotional shock or a sudden stressor. The good news: most people make a complete recovery. The Takeaway We want to hear from you! Please complete our survey: org/member-feedback. Drop us a line at our social media channels: Facebook// Instagram // YouTube. Find out where you stand heart-wise by making an appointment with your primary care physician. Visit the Healthy Living Resource Center for wellness tips, information and resources; 1199SEIUBenefits.org/healthyliving. Get to know your numbers at 1199SEIUBenefits.org/healthyhearts. Get inspired by fellow members through our Members' Voices series: 1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on managing stress, building healthy meals and more: 1199SEIUBenefits.org/videos. Visit our YouTube channel to view a wide collection of healthy living videos: youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: 1199SEIUBenefits.org/wellnessevents. Guest Bio Dr. Shivani Verma is an Interventional Cardiologist at Maimonides Medical Center. With specialized fellowships in Interventional Cardiology and Cardio-Oncology, she brings a wealth of expertise and experience to the field of cardiovascular care. She completed the majority of her training (Internal Medicine, Cardiology, and Interventional Cardiology) at Maimonides, where she gained a deep understanding of the intricacies of diagnosing and treating various cardiac conditions. Her subsequent fellowships highlight her ability to perform complex procedures such as angioplasties and stent placements to restore blood flow to the heart and prevent heart attacks. She also completed a fellowship in cardio-oncology at Memorial Sloan Kettering Cancer Center, where she learned to manage the unique cardiovascular risks that cancer patients face during treatment. Dr. Verma has developed a comprehensive approach to cardiovascular care focused on providing personalized, evidence-based treatment plans that take into account each patient's unique medical history, lifestyle and goals. She prides herself on optimizing the patient-physician relationship to best serve her patients. Additionally, Dr. Verma serves as the Associate Program Director of the Interventional Cardiology Fellowship Program at Maimonides Medical Center. 

In today's episode, supported by Genentech, we had the pleasure of speaking with Komal Jhaveri, MD, FACP, about the clinical use of inavolisib (Itovebi) for patients with hormone receptor (HR)–positive, PIK3CA-mutated, locally advanced or metastatic breast cancer. Dr Jhaveri is section head of the Endocrine Therapy Research Program, clinical director of the Early Drug Development Service, and the Patricia and James Cayne Chair for Junior Faculty at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Jhaveri discussed the importance of having a PI3K inhibitor available for the treatment of patients with HR-positive metastatic breast cancer, advice for managing inavolisib-related adverse effects, and best practices for early biomarker testing in patients with breast cancer.

What if your greatest challenges were actually your most profound teachers?  In this soul-stirring conversation, educator and writer Daphne Gregory-Thomas weaves together the threads of loss, resilience, and transformation through her journey as an innovative educator, cancer survivor, and storyteller. Her narrative illuminates how life's greatest challenges often become our most profound teachers, from early maternal loss to creating groundbreaking educational programs for students with learning differences, and ultimately facing her own mortality through cancer diagnosis and recovery.  Through her raw authenticity and deep wisdom, Daphne reveals how staying open to life's lessons - whether they come from students, strangers on New York City streets, or her own healing journey - has shaped her understanding of purpose and meaning. Her story reminds us that every moment holds the potential for transformation if we remain receptive to the teachers who appear in unexpected forms, from classroom students to cancer diagnoses, each offering their unique wisdom for those willing to listen.  Daphne Gregory-Thomas is an essayist and educational innovator who spent 45 years as a high school educator in the New York/New Jersey area, specializing in programs for students with learning differences. After retiring and overcoming two cancer diagnoses, she became a patient-to-patient volunteer at Memorial Sloan Kettering Cancer Center and discovered her voice as a writer through their Visible Ink program. A passionate advocate for authentic living and self-advocacy, Daphne's work focuses on finding wisdom in life's challenges and staying open to unexpected teachers. Her essays explore resilience, transformation, and the power of sharing our stories.  In This Episode:   (00:00) Introduction to Daphne Gregory-Thomas and her background in education (02:16) Early life experiences and learning from her children as teachers (07:38) Creating an innovative program for students with learning differences (09:29) Impact of student's death and continued advocacy (10:41) The inspiring story of student advocacy and transformation (13:05) Impact of the program over 40 years and breaking educational barriers (15:01) Journey through second cancer diagnosis and life-changing decisions (17:37) Finding strength and wisdom from strangers on New York City streets (19:11) Discovering writing through Visible Ink and service as patient volunteer (21:11) Learning from grandchildren and everyday moments, developing intuition and believing in meaningful connections (24:26) Finding balance and gradual transformation Like and subscribe to hear all of our inspirational episodes!  Resources: Daphne Gregory-Thomas LinkedIn  Daphne Gregory-Thomas on Instagram Daphne Gregory-Thomas on Medium Memorial Sloan Kettering Visible Ink writing program  Sign up for Dara's Newsletter Listen to other podcast episodes Here Connect with Dara on Instagram and Facebook Visit DaraLevan.com 

Subscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsIn this episode, Dr. Taz discusses the underappreciated significance of ovarian health with Dr. Piraye Beim, a pioneering biologist and women's health advocate. Dr. Beim reveals startling insights into the ovary as a metabolic, immune, and endocrine organ, and she shares how ovarian function is misaligned with modern human lifespans. The conversation also covers Dr. Beim's revolutionary work in ovarian health and longevity. Dr. Beim also shares practical advice on lifestyle changes to optimize ovarian health and addresses the future of reproductive medicine. Join us in understanding why ovarian health deserves more attention and how it can shape the future of women's health.About Dr. Piraye BeimPiraye Yurttas Beim, PhD is the founder and CEO of Celmatix, a preclinical-stage biotech transforming women's lives through better ovarian health.  With its growing pipeline of innovative drug programs including an AMHR2 agonist program focused on ovarian aging and an oral FSH for infertility, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Dr. Beim has dedicated herself to innovating in women's health for more than 20 years. During her PhD work at Cornell University (Weill, NYC) and Memorial Sloan Kettering Cancer Center, she was on the front lines of the precision medicine revolution in oncology. She then completed her post-doc at the University of Cambridge (UK), focusing on the science of fertility.Thank you to our sponsorTimeline: timeline.com/DRTAZ06:09 The Role of Ovaries in Human Health12:59 The Impact of Inflammation and Metabolism31:56 Potential Benefits for Women with PCOS37:16 Optimizing Ovarian Health Today40:11 Lifestyle Practices to Support Ovarian Health43:24 The Role of Light and Sleep48:45 Endometriosis and Ovarian Health51:00 Inspiration and Future GoalsStay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Connect with Dr. Piraye Beim:https://www.instagram.com/boss_ovary/https://bit.ly/m/Boss_OvaryHost & Production TeamHost: Dr. Taz; Produced by Rainbow Creative (Executive Producer: Matthew Jones; Lead Producer: Lauren Feighan; Editors: Jeremiah Schultz and Patrick Edwards)Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+

Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. CME information and select publications here.

In today's episode, supported by Takeda, we had the pleasure of speaking with Mark B. Geyer, MD, and Elias Jabbour, MD, about updates in the management of Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Geyer is the Adolescent and Young Adult Program leader and the Adult Lymphoblastic Leukemia Program leader in the Leukemia Service, as well as the chair of Quality Assessment in the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center in New York, New York. Dr Jabbour is a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Drs Geyer and Jabbour discussed the use of ponatinib (Iclusig) in patients with Ph-positive ALL as evidenced by key findings from research such as the pivotal phase 3 PhALLCON trial (NCT03589326). They also highlighted the potential efficacy of this agent in combination with blinatumomab (Blincyto) and shared insights on how the safety profile of this agent affects its clinical use.

Dr Enriqueta Felip from the Vall d'Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here

Dr Enriqueta Felip from the Vall d'Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here

In our February episode, we mark American Heart Month with Dr. Shivani Verma, an interventional cardiologist at Maimonides Medical Center. In our conversation, Dr. Verma shares information on what heart health looks like, symptoms to watch for and how early prevention can help ensure better health outcomes. The Takeaway We want to hear from you! Please complete our survey: org/member-feedback. Drop us a line at our social media channels: Facebook// Instagram // YouTube. Find out where you stand heart-wise by making an appointment with your primary care physician. Visit the Healthy Living Resource Center for wellness tips, information and resources; 1199SEIUBenefits.org/healthyliving. Get to know your numbers at 1199SEIUBenefits.org/healthyhearts. Get inspired by fellow members through our Members' Voices series: 1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on managing stress, building healthy meals and more: 1199SEIUBenefits.org/videos. Visit our YouTube channel to view a wide collection of healthy living videos: youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: 1199SEIUBenefits.org/wellnessevents. Guest Bio Dr. Shivani Verma is an Interventional Cardiologist at Maimonides Medical Center. With specialized fellowships in Interventional Cardiology and Cardio-Oncology, she brings a wealth of expertise and experience to the field of cardiovascular care. She completed the majority of her training (Internal Medicine, Cardiology, and Interventional Cardiology) at Maimonides, where she gained a deep understanding of the intricacies of diagnosing and treating various cardiac conditions. Her subsequent fellowships highlight her ability to perform complex procedures such as angioplasties and stent placements to restore blood flow to the heart and prevent heart attacks. She also completed a fellowship in cardio-oncology at Memorial Sloan Kettering Cancer Center, where she learned to manage the unique cardiovascular risks that cancer patients face during treatment. Dr. Verma has developed a comprehensive approach to cardiovascular care focused on providing personalized, evidence-based treatment plans that take into account each patient's unique medical history, lifestyle and goals. She prides herself on optimizing the patient-physician relationship to best serve her patients. Additionally, Dr. Verma serves as the Associate Program Director of the Interventional Cardiology Fellowship Program at Maimonides Medical Center. 

Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. CME information and select publications here.

There's been a massive gap in oncology where people who have been responsible for a dramatic increase in the standard of care have lacked a solid understanding of the business, payment and policy constructs required to deliver it. Dr. Stephen Schleicher has spent the early part of his career working to fill that gap.Dr. Schleicher entered medical school with an interest in oncology, anchored by an appreciation for the psychological toll cancer can have on a person, their family and caregivers that he gained from parents who were both psychologists. During his internal medicine residency at Brigham and Women's Hospital, Dr. Schleicher also worked at McKinsey and earned his MBA at Harvard Business School as part of a fully-funded fellowship. Through this combined experience, he started to develop a niche in the oncology space where clinical, business and policy decisions intersect, at a time when value-based care was just starting to gain momentum.After a fellowship at Memorial Sloan Kettering Cancer Center, Dr. Schleicher joined Tennessee Oncology, one of the nation's largest community-based cancer care practices, and shortly after became medical director of value-based care at OneOncology, a large community oncology network founded by Tennessee Oncology that spans multiple states. He subsequently returned his focus to Tennessee Oncology where he served as chief medical officer for two years and still practices as a breast cancer medical oncologist. Dr. Schleicher is also a board member and executive committee member at the Community Oncology Alliance.To set the stage for a Healthcare is Hard series focused on Oncology, Dr. Schleicher talked to Keith Figlioli about both the clinical and business trends influencing cancer care. Topics they discussed include:Community providers vs. health systems. For Dr. Schleicher, the ultimate goal is to give cancer patients the personal feel of a community clinic with the resources – including access to precision medicine and clinical trials – that have historically only existed at academic medical centers. While Dr. Schleicher firmly believes that nearly all cancer care should be delivered outside the hospital, he recognizes the expertise for certain conditions – like rare sarcomas – that only exists at academic medical centers and discussed the dynamics of “coopetition” that exists between health systems and community providers in markets across the country.Oncology's cost center. Drugs already account for a significant portion of spending on oncology care, and with dozens of new FDA approvals for cancer therapies each year – some with extremely high costs – this trend will continue. But there are many other variables contributing to the large percentage of spending that goes towards drugs, including the shift from infusions to more oral medication. Dr. Schleicher explains how reliance on oral medication introduces PBMs and specialty pharmacies into the equation, which can add cost and complexity, and sometimes slow the speed of critical care.The value based care dilemma. Dr. Schleicher talked about how successful The CMS Oncology Care Model (OCM) was at optimizing care for Tennessee Oncology's patients. He says hospitalizations and ER visits went from 20%-30% of costs before OCM to less than 10% now. The remaining 90% of costs now goes towards drugs – even when used appropriately following pathways. The dilemma is that there isn't too much more room for cost improvement in care delivery. Dr. Schleicher discussed how payers need a better understanding of how to incentivize providers around costs they can control, while allowing for expensive therapies if they're the right drug at the right time to improve costs and outcomes in the long run.To hear Stephen and Keith discuss these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

Dr. Stéphanie Gaillard and Dr. Bill Tew share updates to the evidence-based guideline on neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer. They highlight recommendations across ten clinical questions, addressing initial assessment, primary cytoreductive surgery, neoadjuvant chemotherapy (NACT), tests and/or procedures that should be completed before NACT, preferred chemotherapy regimens, timing of interval cytoreductive surgery (ICS), hyperthermic intraperitoneal chemotherapy (HIPEC), post ICS-chemotherapy, maintenance therapy, and options for those without a clinical response to NACT. They highlight the evidence supporting these recommendations and emphasize the importance of this guideline for clinicians and patients. Read the full guideline update, “Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update” at www.asco.org/gynecologic-cancer-guidelines." TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology. Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Stéphanie Gaillard from Johns Hopkins University and Dr. Bill Tew from Memorial Sloan Kettering Cancer Center, co-chairs on “Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.” Thank you for being here today, Dr. Gaillard and Dr. Tew. Dr. Bill Tew: Thank you for having us. Dr. Stéphanie Gaillard: Yeah, thank you. It's great to be here. Brittany Harvey: Great. Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Gaillard and Dr. Tew, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the content here, first, Dr. Tew, could you describe what prompted this update to the neoadjuvant chemotherapy for ovarian cancer guideline? And what is the scope of this update? Dr. Bill Tew: Yeah. It's been almost a decade since ASCO first published its neoadjuvant chemotherapy guidelines for women with newly diagnosed ovarian cancer, and over that 10-year period, there's really been a major shift in how oncologists treat patients in the U.S. If you look at the National Cancer Database, between 2010 and 2021, the proportion of patients with advanced ovarian cancer who underwent primary surgery fell from about 70% to about 37%. And there's been a doubling in the amount of neoadjuvant chemotherapy used. So we wanted to take a look at that and really both highlight the appropriate patient populations for primary surgery versus new adjuvant chemotherapy, as well as review any studies that have been published since then. There's been, I think, about 61 trials published, nine randomized trials alone in the last 10 years. And the scope of the guideline was really not only the neoadjuvant chemotherapy and surgical questions, but also to touch upon some new treatments that have come to the forefront in newly diagnosed ovarian cancer, including heated intraperitoneal chemotherapy or HIPEC, as well as the integration of maintenance therapy, particularly bevacizumab and PARP inhibitors. Brittany Harvey: Understood. That's a large amount of new evidence to review in this Update. Then, next, Dr. Gaillard, I'd like to review the key recommendations across the 10 clinical questions that the guideline addressed. So, starting with: What is recommended regarding initial assessment for patients with newly diagnosed pelvic masses and/or upper abdominal or peritoneal disease? Dr. Stéphanie Gaillard: Sure. So in talking about the first guidelines, the first one that we addressed was how to do the initial assessment for these patients. And first, and probably most critically, it's important to recognize that these patients really should be evaluated by a gynecologic oncologist prior to initiation of any therapy, whether that means a primary cytoreductive surgery or neoadjuvant chemotherapy, because really, they are the best ones to determine the pathway that the patient should take. The initial assessment should involve a CA-125, a CT of the abdomen and pelvis with oral and IV contrast, if not contraindicated, and then also chest imaging, in which a CT is really the preferred modality. And that helps to evaluate the extent of disease and the feasibility of the surgical resection. Now, there may be some other tools that could be helpful to also refine this assessment. So, for example, a laparoscopy can really help to determine the feasibility of surgical resection as well as the extent of disease. Further imaging, such as diffusion-weighted MRI or FDG-PET scans can be helpful, as well as ultrasounds. And then also an endometrial biopsy. And that was newly added because there really has been a divergence of treatment for endometrial cancer versus ovarian cancer. And so it's really important to determine upfront where the source of the disease is coming from. Brittany Harvey: I appreciate you describing those recommendations surrounding initial assessment. So following this assessment, Dr. Tew, which patients with newly diagnosed advanced epithelial ovarian cancer should be recommended primary cytoreductive surgery? Dr. Bill Tew: The key thing here is if the GYN oncology surgeon feels that they have a high likelihood of achieving a complete cytoreduction with acceptable morbidity, the panel overwhelmingly agrees that primary cytoreduction surgery should be recommended over chemotherapy. And we know that surgery is really the cornerstone to achieving clinical remission. And our concern is that neoadjuvant chemotherapy may be overused in this fit population. Sometimes it is challenging to determine truly if a patient has a high likelihood of complete cytoreduction or what is acceptable morbidity. But an evaluation with performance status, fitness, looking at age or frailty, nutritional status, as well as a review of imaging studies to plan and determine for who is the right patient for primary surgery is key. Brittany Harvey: And then the title of this guideline, Dr. Gaillard, for which patients is neoadjuvant chemotherapy recommended? Dr. Stéphanie Gaillard: Yeah. So there's really two patient populations that we think are best suited to receive neoadjuvant chemotherapy. Those may be patients who are fit for a primary cytoreductive surgery, but they're unlikely to have a complete cytoreduction if they were to go to surgery directly. And so that's where neoadjuvant chemotherapy can be very helpful in terms of increasing the ability to obtain a complete cytoreduction. The second population is those who are newly diagnosed who have a high perioperative risk, and so they're not fit to go to surgery directly. And so it may be better to start with neoadjuvant chemotherapy and then do an interval cytoreductive surgery. Again, I just want to emphasize the importance of including a gynecologic oncologist when making these determinations for patients. Brittany Harvey: Absolutely. So then the next clinical question. Dr. Tew, for those patients with newly diagnosed stage 3 to 4 epithelial ovarian cancer, what tests and or procedures are recommended before neoadjuvant chemotherapy is delivered? Dr. Bill Tew: The key test is to confirm the proper diagnosis, and that requires histological confirmation with a core biopsy. And this was a point the panel strongly emphasized, which is a core biopsy is a much better diagnostic tool compared to cytology alone. But there will be cases, exceptional cases, where a core biopsy cannot be performed. And in those settings, cytology combined with serum CA-125 and CEA is acceptable to exclude a non-gynecologic cancer. The other reason why cord biopsy is strongly preferred is because we already need to start thinking about germline and somatic testing for BRCA1 and 2. This information is important as we start to think about maintenance strategies for our patients. And so having that information early can help tailor the first-line chemotherapy regimen. Brittany Harvey: So then you've described who should be receiving neoadjuvant chemotherapy, but Dr. Gaillard, for those who are receiving neoadjuvant chemo, what is the preferred chemotherapy regimen? And then what does the expert panel recommend regarding timing of interval cytoreductive surgery? Dr. Stéphanie Gaillard: Sure. So for neoadjuvant chemotherapy, we generally recommend a platinum taxane doublet. This is especially important for patients with high grade serous or endometrioid ovarian cancers, and that's really because this is what the studies had used in the neoadjuvant trials. We recognize, however, that sometimes there are individual patient factors, such as advanced age or frailty, or certain disease factors such as the stage or rare histology that may shift what is used in terms of chemotherapy, but the recommendation is to try to stick as much as possible to the platinum taxane doublet. And then in terms of the timing of interval cytoreductive surgery, this was something that the panel discussed quite a bit and really felt that it should be performed after four or fewer cycles of neoadjuvant chemotherapy, especially in patients who've had a response to chemotherapy or stable disease. Sometimes alternative timing of surgery can be considered based on some patient centered factors, but those really haven't been prospectively evaluated. The studies that looked at neoadjuvant chemotherapy usually did the interval cytoreductive surgery after three or four cycles of chemotherapy. Brittany Harvey: For those patients who are receiving interval cytoreductive surgery, Dr. Tew, earlier in the podcast episode, you mentioned a new therapy. What is recommended regarding hyperthermic intraperitoneal chemotherapy? Dr. Bill Tew: Yeah, or simply HIPEC as everyone refers to it. You know, HIPEC isn't really a new therapy. HIPEC is a one-time perfusion of cisplatin, which is a chemotherapy that has been a standard treatment for ovarian cancer for decades. But the chemotherapy is heated and used as a wash during the interval cytoreductive surgery. And since our last guideline, there has been a publication of a randomized trial that looked at the use of HIPEC in this setting. And in that study there was improved disease-free and overall survival among the patients that underwent HIPEC versus those that did not. So we wanted to at least emphasize this data. But we also wanted to recognize that HIPEC may not be available at all sites. It's resource-intensive. It requires a patient to be medically fit for it, particularly renal function and performance status. And so it's something that could be discussed with the patient as an option in the interval cytoreductive surgery. One other point, the use of HIPEC during primary surgery or later lines of therapy still is unknown. And the other point is this HIPEC trial came prior to the introduction of maintenance PARP inhibitors. So there's still a lot of unknowns, but it is a reasonable option to discuss with appropriate patients. Brittany Harvey: I appreciate you reviewing that data and what that updated recommendation is from the panel. So then, Dr. Gaillard, after patients have received neoadjuvant chemotherapy and interval cytoreductive surgery, what is the post ICS chemotherapy recommended? Dr. Stéphanie Gaillard: The panel recommends some post ICS chemotherapy, as you mentioned. This is typically to continue the same chemotherapy that was done as neoadjuvant chemotherapy and so preferably platinum and taxane. And typically we recommend a total of six cycles of treatment, although the exact number of cycles that is given post-surgery can be adjusted based on different patient factors and their response to treatment. Importantly, also, timing is a factor, and we recommend that postoperative chemotherapy begin within four to six weeks after surgery, if at all feasible. Brittany Harvey: Absolutely. Those timing recommendations are key as well. So then, Dr. Tew, you mentioned this briefly earlier, but what is the role of maintenance therapy? Dr. Bill Tew: Maintenance therapy could be a full podcast plus of discussion, and it's complicated, but we did want to include it in this guideline in part because the determination of whether to continue treatment after completion of surgery and platinum based therapy is key as one is delivering care in the upfront setting. So first off, when we say maintenance therapy, we are typically referring to PARP inhibitors or bevacizumab. And I would refer listeners to the “ASCO PARP Inhibitor Guideline” that was updated about two years ago, as well as look at the FDA-approved label indications. But in general, PARP inhibitors, whether it's olaparib or niraparib, single agent or olaparib with bevacizumab, are standard treatments as maintenance, particularly in those patients with a germline or somatic BRCA mutation or those with an HRD score positive. And so it's really important that we emphasize germline and somatic BRCA testing for all patients with newly diagnosed ovarian cancer so that one can prepare for the use of maintenance therapy or not. And the other point is, as far as bevacizumab, bevacizumab is typically initiated during the chemotherapy section of first-line treatment. And in the guidelines we gave specific recommendations as far as when to start bevacizumab and in what patient population. Brittany Harvey: Great. Yes. And the PARP inhibitors guideline you mentioned is available on the ASCO guidelines website and we can provide a link in the show notes for our listeners. So then, the last clinical question, Dr. Gaillard, what treatment options are available for patients without a clinical response to neoadjuvant chemotherapy? Dr. Stéphanie Gaillard: Yeah, this is a tough situation. And so it's important to remember that ovarian cancer typically does respond to chemotherapy initially. And so it's unusual to have progressive disease to neoadjuvant chemotherapy. So it's really important that if someone has progressive disease that we question whether we really have the right diagnosis. And so it's important to, I think at that point, obtain another biopsy and make sure that we know what we're really dealing with. In addition, this is where Dr. Tew mentioned getting the molecular profiling and genetic testing early in the course of disease. If that hasn't been done at this point in time, it's worth doing that in this setting so that that can also potentially help guide options for patients. And patients who are in those situations, really, the options are other chemotherapy regimens, clinical trials may be an option, or in some situations, if they have really rapidly progressing disease that isn't amenable to further therapy, then initiation of end-of-life care would be appropriate. Brittany Harvey: I appreciate you both for reviewing all of these recommendations and options for patients with advanced ovarian cancer. So then to wrap us up, in your view, what is both the importance of this guideline update and how will it impact clinicians and patients with advanced ovarian cancer? Dr. Bill Tew: Well, first off, I'm very proud of this guideline and the panel that I work with and Dr. Gaillard, my co-chair. The guideline really pulls together nicely all the evidence in a simple format for oncologists to generate a plan and determine what's the best step for patients. The treatment of ovarian cancer, newly diagnosed, is really a team approach - surgeons, medical oncologists, and sometimes even general gynecologists - and understanding the data is key, as well as the advances in maintenance therapy and HIPEC. Dr. Stéphanie Gaillard: For my part, I'd say we hope that the update really provides physicians with best practice recommendations as they navigate neoadjuvant chemotherapy decisions for their patients who are newly diagnosed with ovarian cancer. There is a lot of data out there and so we hope that we've synthesized it in a way that makes it easier to digest. And along that regard, I really wanted to give a special shout out to Christina Lacchetti, who just put in a tremendous effort in putting these guidelines together and in helping to coordinate the panel. And so we really owe a lot to her in this effort. Dr. Bill Tew: Indeed. And ASCO, as always, helps guide and build a great resource for the oncology community. Brittany Harvey: Absolutely. Yes, we hope this is a useful tool for clinicians. And I want to thank you both for the large amount of work you put in to update this evidence-based guideline. And thank you for your time today, Dr. Gaillard and Dr. Tew. Dr. Stéphanie Gaillard: Thank you. Dr. Bill Tew: Thank you for having us. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/gynecologic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the latest highlights from ASH 2024, focusing on key studies in lymphoma. In this episode, we dive into: •⁠  ⁠POLARIX Study: An update on the POLARIX trial, exploring the use of Polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL) and its impact on progression-free survival (PFS). •⁠  ⁠inMIND Study: A look at the promising results of the inMIND study, which evaluates the combination of Tafasitamab with Lenalidomide and Rituximab in the second-line setting for follicular lymphoma. •⁠  ⁠Triangle Study: Insights into the evolving role of transplant in mantle cell lymphoma and the implications of BTK inhibitors in treatment. •⁠  ⁠ENRICH Study: Discussion on the potential of Ibrutinib combined with Rituximab in the first-line setting and its comparison to traditional chemoimmunotherapy. Join us as we unpack these practice-changing studies, discuss their implications for clinical practice, and share insights on managing side effects associated with new therapies. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice! #OncologyBrothers #ASH2024 #Lymphoma #CancerResearch #Podcast

Welcome to Paranormal Spectrum, where we illuminate the enigmatic corners of the supernatural world. I'm your host, Barnaby Jones, and today we have a very special guest joining us:Bruce Rapuano a B.A. degree from the University of Pennsylvania where he majored in Neurobiology and minored in Psychology, a Ph.D. in Neuropharmacology from the University of Connecticut and a J.D. from New York Law School. Dr. Rapuano has conducted independent biomedical research as a cell biologist at internationally recognized medical institutions including the Memorial Sloan-Kettering Cancer Center and the Hospital for Special Surgery, both located in New York City. He has authored or coauthored thirty scientific articles in peer-reviewed medical journals. He has published articles on topics such as the role of membrane phospholipids in nerve function, the skeletal effects of cancer metastases, metabolic bone diseases and the coordinate surface electrical and biological properties of titanium alloy implant materials. Dr. Rapuano has also worked concurrently as a medical research scientist and Associate Radiation Safety Officer at the Hospital for Special Surgery.This bombshell nonfiction book, recently discussed by the author with George Knapp on Coast to Coast AM, is the only first-person account to date of UFO alien abductions authored by a mainstream American scientist. The author, who has multiple degrees in neuroscience, goes on the record regarding his incredible and fascinating experiences with UFO close encounters, including a very close encounter during which he was abducted from a group of eight other witnesses, interactions with alien beings and an unexplained nasal implant of specific structure all of which were consciously recalled without regressive hypnosis. The detailed conscious recollection of these experiences, including unexplained physiological effects and physical scars, checks every box in the modern core alien abduction scenario AND predated the publishing of any other books on alien abduction. Another remarkable aspect to this book is the fact that it is the first to explain exactly how the grey aliens were genetically reengineered from our early hominin ancestors. Also riveting are the author's interactions with short humanoid beings that are described in captivating detail to reveal all the ways that aliens control human behavior during the abduction process possibly with the aid of neural implants.This is the story of a mainstream scientist's own interactions with the highly advanced alien beings who abducted him and at least thousands of other people. As discussed in Dominion Lost, compelling technological evidence of the alien presence, especially with respect to incredibly advanced UFO propulsion systems and implanted devices that are likely instruments of mind control, has existed on this planet for more than 60 years. More importantly, this book is a wake-up call to our species to finally accept the reality that we are now sharing our world with technologically superior alien beings. This new reality must be addressed immediately.https://www.amazon.com/DOMINION-LOST-Abridged-Bruce-Rapuano/dp/B0CQGDXV8NClick that play button, and let's unravel the mysteries of the UNTOLD! Remember to like, share, and subscribe to our channel to stay updated on all the latest discoveries and adventures. See you there!Join Barnaby Jones on the Paranormal Spectrum every Thursday on the Untold Radio Network Live at 12pm Central – 10am Pacific and 1pm Eastern. Come and Join the live discussion next week. Please subscribe.We have twelve different Professional Podcasts on all the things you like. New favorite shows drop each day only on the UNTOLD RADIO NETWORK.To find out more about Barnaby Jones and his team, (Cryptids, Anomalies, and the Paranormal Society) visit their website www.WisconsinCAPS.comMake sure you share and Subscribe to the CAPS YouTube Channel as wellhttps://www.youtube.com/channel/UCs7ifB9Ur7x2C3VqTzVmjNQ

Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia.

Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and moderator Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCML24).

How can urologists run clinical trials efficiently while improving enrollment and reducing costs? In this episode of the BackTable Urology Podcast, Dr. Behfar Ehdaie, a urologic oncologist at Memorial Sloan Kettering Cancer Center, joins host Dr. Aditya Bagrodia to discuss methods and practical implementation strategies for clinical trials in urology. --- This podcast is supported by: Photocure https://www.photocure.com/ --- SYNPOSIS First, Dr. Ehdaie shares personal experiences from starting pilot trials, engaging stakeholders, and integrating trial processes into clinical practice. He also discusses mechanisms to reduce cost and improve enrollment while explaining the concept of two-stage consent to minimize patient anxiety. This episode aims to provide valuable pearls for young investigators and experienced practitioners alike on conducting successful clinical trials. --- TIMESTAMPS 00:00 - Introduction 04:39 - Challenges in Clinical Trials 06:21 - Case Study: Focal Therapy Trial 16:45 - Case Study: Hernia Trial 20:17 - Innovation in Clinical Trials 26:25 - Two-Stage Consent 36:11 - Final Thoughts --- RESOURCES Photocure https://www.photocure.com/

The FDA recently issued a rule that requires all mammography reports include information about breast density. Abdul talks to Dr. Elise Desperito, the Breast Imaging Director at Memorial Sloan Kettering Cancer Center about what breast density is and its implications for breast cancer screening. To assess your breast cancer risk, Memorial Sloan Kettering Cancer Center recommends the Tyrer-Cuzick Risk Assessment Calculator. This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: Marguerite Casey Foundation: Join the MCF Book Club at CaseyGrants.org/BookClub. Quince: Upgrade your wardrobe with pieces made to last with Quince. Go to Quince.com/AD for free shipping on your order and 365-day returns. Lumen: If you want to take the next step in improving your health, visit go.lumen.me/AD for 15% off your purchase. To See Each Other: A podcast that complicates the narrative about small town Americans in our most misunderstood communities. You can listen to more episodes of To See Each Other at https://link.chtbl.com/toseeeachother?sid=americadissected.